No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 4,560 | 5,212 | 5,215 | 5,549 | 5,810 | 6,293 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | 448 | 524 | 223 | 263 | 412 | 638 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
